References

Prostate cancer: a review

10.1001/jama.2025.0228 · 2025 · External reference

Recent patterns and trends in global prostate cancer incidence and mortality: an update

10.1016/j.eururo.2024.11.013 · 2025 · External reference

Castration-resistant prostate cancer: mechanisms, targets and treatment

10.1007/978-3-319-99286-0_7 · 2018 · External reference

Characterising the castration-resistant prostate cancer population: a systematic review

10.1111/j.1742-1241.2011.02799.x · 2011 · External reference

Navigating the evolving therapeutic landscape in advanced prostate cancer

10.1016/j.urolonc.2017.01.020 · 2017 · External reference

PARP inhibitors in metastatic prostate cancer: evidence to date

10.2147/cmar.s227033 · 2020 · External reference

PARP inhibitors in castration-resistant prostate cancer

2020 · External reference

Current therapy and drug resistance in metastatic castration-resistant prostate cancer

10.1016/j.drup.2023.100962 · 2023 · External reference

A view on drug resistance in cancer

10.1038/s41586-019-1730-1 · 2019 · External reference

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

2015 · External reference

Therapeutic resistance models and treatment sequencing in advanced prostate cancer

10.3390/cancers15215273 · 2023 · External reference

Molecular chess? Hallmarks of anti-cancer drug resistance

10.1186/s12885-016-2999-1 · 2017 · External reference

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance

10.1101/mcs.a003657 · 2019 · External reference

Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors

10.1158/2159-8290.cd-17-0146 · 2017 · External reference

Olaparib-induced senescence is bypassed through G2–M checkpoint override in olaparib-resistant prostate cancer

10.1158/1535-7163.mct-21-0604 · 2022 · External reference

PINK1-Mediated mitochondrial activity confers olaparib resistance in prostate cancer cells

10.1158/2767-9764.crc-24-0339 · 2024 · External reference

Altered metabolism in cancer: insights into energy pathways and therapeutic targets

10.1186/s12943-024-02119-3 · 2024 · External reference

The emerging hallmarks of cancer metabolism

10.1016/j.cmet.2015.12.006 · 2016 · External reference

Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance

10.1038/ncb1258 · 2005 · External reference

The Parkinson’s gene PINK1 regulates cell cycle progression and promotes cancer-associated phenotypes

10.1038/onc.2014.81 · 2015 · External reference

Steroid sulfatase regulates metabolic reprogramming in advanced prostate cancer

10.3390/cancers17121959 · 2025 · External reference

Oxidative phosphorylation as an emerging target in cancer therapy

10.1158/1078-0432.ccr-17-3070 · 2018 · External reference

Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications

10.1016/j.semcancer.2022.02.002 · 2022 · External reference

Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy

10.1186/s12943-024-02205-6 · 2025 · External reference

The effect of oxidative phosphorylation on cancer drug resistance

10.3390/cancers15010062 · 2023 · External reference

Mitochondrial respiratory complex I: structure, function and implication in human diseases

10.2174/092986709787846578 · 2009 · External reference

Mitochondrial complex I

10.1146/annurev-biochem-070511-103700 · 2013 · External reference

Mammalian mitochondrial complex I structure and disease-causing mutations

10.1016/j.tcb.2018.06.006 · 2018 · External reference

NDUFS4 promotes tumor progression and predicts prognosis in gastric cancer

10.1093/carcin/bgac074 · 2022 · External reference

Low VDAC1 expression is associated with an aggressive phenotype and reduced overall patient survival in cholangiocellular carcinoma

10.3390/cells8060539 · 2019 · External reference

Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention

10.1093/brain/awab426 · 2022 · External reference

Casticin impairs cell migration and invasion of mouse melanoma B16F10 cells via PI3K/AKT and NF-κB signaling pathways

10.1002/tox.22417 · 2017 · External reference

Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis

10.1172/jci139933 · 2021 · External reference

Constitutive reprogramming of fibroblast mitochondrial metabolism in pulmonary hypertension

10.1165/rcmb.2015-0142oc · 2016 · External reference

Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors

10.1002/cjp2.247 · 2022 · External reference

NDUFS4 regulates cristae remodeling in diabetic kidney disease

10.1038/s41467-024-46366-w · 2024 · External reference

IQGAP1 mediates the communication between the nucleus and the mitochondria via NDUFS4 alternative splicing

10.1093/narcan/zcad046 · 2023 · External reference

Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer

10.1186/s12943-024-02165-x · 2024 · External reference

Mitochondrial metabolism as a target for cancer therapy

10.1016/j.cmet.2020.06.019 · 2020 · External reference

Ferroptosis in cancer therapy: a novel approach to reversing drug resistance

10.1186/s12943-022-01530-y · 2022 · External reference

RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis

10.1172/jci166647 · 2023 · External reference

Specific knockdown of the NDUFS4 gene reveals important roles of ferroptosis in UVB-induced photoaging

10.1007/s10753-024-02057-8 · 2025 · External reference

Iron status influences mitochondrial disease progression in Complex I-deficient mice

10.7554/elife.75825 · 2023 · External reference

The biology and toxicology of molluscicides, bayluscide

10.1016/0163-7258(82)90064-x · 1982 · External reference

The magic bullet: niclosamide

10.3389/fonc.2022.1004978 · 2022 · External reference

Beyond an antihelminthic drug

10.1016/j.cellsig.2017.04.001 · 2018 · External reference

Extracellular pH modulates neuroendocrine prostate cancer cell metabolism and susceptibility to the mitochondrial inhibitor niclosamide

10.1371/journal.pone.0159675 · 2016 · External reference

Progress in redirecting antiparasitic drugs for cancer treatment

10.2147/dddt.s308973 · 2021 · External reference

Induction of oxidative stress and ferroptosis in triple-negative breast cancer cells by niclosamide via blockade of the function and expression of SLC38A5 and SLC7A11

10.3390/antiox13030291 · 2024 · External reference

Impact of oncogenic changes in p53 and KRAS on macropinocytosis and ferroptosis in colon cancer cells and anticancer efficacy of niclosamide with differential effects on these two processes

10.3390/cells13110951 · 2024 · External reference

ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling

10.1038/s41388-021-01914-2 · 2021 · External reference

Structure–activity relationship of niclosamide derivatives

2017 · External reference

IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer

10.1016/j.isci.2024.108984 · 2024 · External reference

Characteristics and biomarkers of ferroptosis

10.3389/fcell.2021.637162 · 2021 · External reference

Ferroptosis: molecular mechanisms and health implications

10.1038/s41422-020-00441-1 · 2021 · External reference

NRF2, a superstar of ferroptosis

10.3390/antiox12091739 · 2023 · External reference

NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis

10.1016/j.redox.2019.101107 · 2019 · External reference

Accessory subunit NUYM (NDUFS4) is required for stability of the electron input module and activity of mitochondrial complex I

10.1016/j.bbabio.2016.11.010 · 2017 · External reference

Accessory subunits of the matrix arm of mitochondrial complex I with a focus on subunit NDUFS4 and its role in complex I function and assembly

2021 · External reference

Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies

10.1038/s41392-024-01769-5 · 2024 · External reference

Ferroptosis: an emerging therapeutic opportunity for cancer

10.1016/j.gendis.2020.09.005 · 2022 · External reference

Pharmacological advances and therapeutic applications of niclosamide in cancer and other diseases

10.1016/j.ejmech.2025.117527 · 2025 · External reference

Discovery of novel potent covalent glutathione peroxidase 4 inhibitors as highly selective ferroptosis inducers for the treatment of triple-negative breast cancer

10.1021/acs.jmedchem.3c00967 · 2023 · External reference

Iron and siRNA co-encapsulated ferritin nanocages induce ferroptosis synergistically for cancer therapy

10.1016/j.apsb.2024.10.006 · 2025 · External reference

Iron overload enhances the susceptibility to cysteine deprivation-induced ferroptosis in non-small cell lung cancer cells

10.1007/s12032-025-02757-7 · 2025 · External reference